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In a study of 110 Pseudomonas cepacia isolates from patients without cystic fibrosis, the in vitro potencies of
three new compounds, meropenem, PD 127391, and PD 131628, were comparable to those of ceftazidime and
ciprofloxacin and exceeded those of chloramphenicol and co-trimoxazole. The MICs of ceftazidime, ciproflox-
acin, meropenem, and the PD compounds for 90% of strains tested were c4 ,ug/ml, whereas they were 32
,ug/ml for chloramphenicol and co-trimoxazole. Data for 20 isolates from patients with cystic fibrosis indicated
that the isolates were less susceptible to all seven antibiotics tested, with the most active compounds being
meropenem and PD 127391.
Pseudomonas cepacia, a phytopathogen first described as
the cause of soft rot of onions (4), is now recognized as a
significant opportunistic pathogen in patients with nosoco-
mial infections (9, 12). Patients with cystic fibrosis (CF)
appear to be particularly susceptible to pulmonary coloniza-
tion with this organism (2, 13, 23, 25): CF patients colonized
with P. cepacia experience more pulmonary exacerbations
and a higher mortality than do noncolonized CF patients
(26).
P. cepacia is innately resistant to a wide range of antibi-
otics and disinfectants including polymyxin, aminoglyco-
sides, and traditional antipseudomonal penicillins such as
ticarcillin (3, 7, 15, 21). It is not surprising, therefore, that P.
cepacia infections are generally refractory to antibiotic
therapy and pose a significant challenge in the management
of patients with CF (9, 10). Historically, the most effective
antibiotics for the treatment of P. cepacia infections were
trimethoprim-sulfamethoxazole and chloramphenicol, al-
though these agents displayed limited clinical efficacy (20,
27). More recently available antibiotics, including ceftazi-
dime, temocillin, imipenem, and ciprofloxacin, exhibit some
in vitro activity against this organism (1, 17, 26). However,
initial clinical experience with some of these compounds has
shown variable benefits (8).
The availability of new agents with in vitro and in vivo
activities against P. cepacia would be of considerable im-
portance in the management of patients with CF. Thus, we
examined a new carbapenem, meropenem, and two more
recently developed quinolones for their activities against a
large collection of P. cepacia isolates, including those from
patients with CF.
Meropenem (ICI 194660 or SM 7338) is a new carbapenem
with an exceptionally broad spectrum of antibacterial activ-
ity (14). Unlike imipenem, which is metabolized by renal
dipeptidases and requires the coadministration of cilastatin,
meropenem is stable to dehydropeptidase-I, and thus, it is
not necessary to coadminister it with cilastatin (6, 18). PD
127391, 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-
fluoro-1,4,dihydro-4-oxo-3-quinolone-carboxylic acid, and
* Corresponding author.
PD 131628, 7-(3-amino-1-pyrrolidinyl)-1-cyclopropyl-6-flu-
oro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid,
are oral quinolones that are being developed by Warner-
Lambert and that may possess pharmacokinetics superior to
those of clinically available 4-quinolones (5, 16). The data
presented here describe the in vitro activities of these
compounds against P. cepacia compared with those of the
most active antibiotics available, ceftazidime, ciprofloxacin,
chloramphenicol, and trimethoprim-sulfamethoxazole (co-
trimoxazole). Most previous in vitro studies of the activity of
meropenem and the two PD compounds have tested only
small numbers of P. cepacia or used collections of
pseudomonads which were not identified to the species level
(5, 14, 16).
In the present study, we investigated a total of 130 P.
cepacia isolated from CF and non-CF patients in France, the
United Kingdom, and the United States. All strains were
identified by standard methods (11), including use of the API
20NE system (API System, La Balme les Grottes, France)
and determination of their ability to grow on a selective
medium (7). The strains included in the study were further
characterized by bacteriocin typing (11, 22); multiple isolates
from individual patients or epidemics belonging to the same
bacteriocin type were excluded from the study. The antibi-
otics used in the study were obtained through the indicated
sources: meropenem (ICI 194660, SM 7338), ICI Pharma-
ceuticals, Macclesfield, United Kingdom; PD 127391 (CI
960), PD 131628 (CI 990), and chloramphenicol, Clinical
Research Northern Europe, Parke-Davis Warner-Lambert,
Eastleigh, United Kingdom; ceftazidime, Glaxo Pharmaceu-
ticals Ltd., Greenford, United Kingdom; ciprofloxacin,
Bayer UK Ltd., Newbury, United Kingdom; and co-trimox-
azole, Wellcome, Bromley, United Kingdom. Determination
of MICs was done by the guidelines of the National Com-
mittee for Clinical Laboratory Standards (19). Bacterial
antibiotic susceptibility tests were performed by an agar
dilution method on Mueller-Hinton agar (Oxoid Ltd., Bas-
ingstoke, United Kingdom), with an initial inoculum of
approximately 104 CFU per spot, by using a multipoint
inoculator (model A400; Denley Instruments Ltd., Sussex,
United Kingdom). The MIC was determined as the lowest
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TABLE 1. MICs of seven antimicrobial agents for 110 non-CF
and 20 CF isolates of P. cepacia
Antimicrobial MIC (,Lg/ml)
agent ~Sourceagent Range 50% 90%
Chlorampenicol Non-CF 1-128 16 32
CF 2-> 128 16 64
Co-trimoxazole Non-CF 0.5-> 128 4 32
CF 4-> 128 32 128
Ceftazidime Non-CF 0.06-> 128 2 4
CF 1-> 128 8 32
Ciprofloxacin Non-CF <0.06-128 1 2
CF 0.25-128 8 128
Meropenem Non-CF <0.06-16 2 4
CF 1-16 2 16
PD 127391 Non-CF <0.06-16 0.5 1
CF 0.12-32 4 16
PD 131628 Non-CF <0.06-64 0.5 1
CF 0.12-128 4 64
concentration of antibiotic that inhibited growth of the test
organism after 48 h of incubation at 37°C.
Details of the in vitro activities of PD 127391 and PD
131628 against 110 non-CF isolates of P. cepacia are given in
Table 1. The activities of PD 127391 and PD 131628 were
compared with those of other relevant antibacterial agents.
On the basis of the MICs for 50% (MIC50s) and 90%
(MIC90s) of isolates tested, both of the new PD quinolone
compounds showed in vitro activities slightly better than
those of ciprofloxacin and ceftazidime and were consider-
ably more active than either co-trimoxazole or chloramphen-
icol. On the basis of similar parameters, meropenem was less
active than the PD compounds at the MIC50s and MIC90s.
For none of the isolates tested were the MICs of meropenem
or PD 127391 greater than 16 ,ug/ml, while for some of the
isolates, MICs of the other antimicrobial agents tested, with
the exception of PD 131628, were 128 ,ug/ml or greater. On
the basis of the published activity of imipenem (24), mero-
penem and the PD compounds were more active at the
MIC50s and MIC90s.
None of the presently available antimicrobial agents has
proved to be effective in the treatment of P. cepacia coloni-
zation in patients with CF, although combination therapy
with temocillin and an aminoglycoside has been reported to
have some clinical effect even against aminoglycoside-resis-
tant isolates (27). Hence, the development of new agents
with in vitro and in vivo activities against P. cepacia would
be an important advance in the management of patients with
CF. The isolates from patients with CF examined in the
present study were less susceptible than isolates from pa-
tients without CF, perhaps reflecting the frequent use of
antibiotics in patients with CF. Nevertheless, on the basis of
their in vitro activities, the carbapenem meropenem and the
new quinolone PD 127391 provide alternative agents with in
vitro activities against P. cepacia that surpass those of the
five other compounds. If the upper limit of susceptibility for
meropenem is taken as 8 ,ug/ml (14), with an MIC50 of 2
,g/ml and an MIC range of 1 to 16 ,ug/ml, most isolates of P.
cepacia from patients with CF examined in the present study
were susceptible. If the upper limit of susceptibility for the
PD compounds is put at 2 to 4 ,ug/ml, as suggested for similar
compounds (28), PD 127391, with an MIC50 of 4 ,ug/ml and
an MIC range of 0.12 to 32 ,ug/ml, appears marginally better
than PD 131628 and the existing quinolone standard cipro-
floxacin.
It is a cause of concern that two strains of P. cepacia that
exhibited resistance to all seven antibiotics tested were
isolated from two patients with CF in Wales and Scotland.
Further investigation of the prevalence of such multiresis-
tant strains is needed to assess future problems in the
management of patients with CF. The MIC data indicate
that, with the exception of the two isolates from patients
with CF in Wales and Scotland, meropenem and the PD
compounds are highly active against isolates of P. cepacia
that are resistant to the four other antibacterial agents
investigated.
We conclude that the overall activities of meropenem and
the PD compounds in in vitro susceptibility tests against a
comprehensive collection of P. cepacia isolates indicate that
these are promising new agents and that further studies of
their pharmacokinetics and clinical efficacies in patients with
CF are needed.
We are grateful to ICI Pharmaceuticals and Park-Davis Warner-
Lambert for support.
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